Bacteria Clinical Development Protein 
Pharmaceutical Technology
AUGUST 17, 2022
VLA15 is the only vaccine for Lyme disease in clinical development, according to GlobalData, the parent company of Pharmaceutical Technology. Lyme disease is also known as borreliosis, which refers to the borrelia bacteria that cause the condition. The vaccine targets six different serotypes of borrelia bacteria.
pharmaphorum
DECEMBER 4, 2020
Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development. VLA15 is the only active Lyme disease vaccine in clinical development today, and covers six strains that are prevalent in North America and Europe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Camargo
JULY 27, 2021
When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.
pharmaphorum
SEPTEMBER 28, 2021
VLA15 targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria that causes Lyme disease, a tick-borne infection that causes a characteristic rash that can be accompanied by flu-like symptoms and – in some cases – debilitating tiredness and aches that can last for years.
pharmaphorum
JUNE 20, 2022
Valneva is on the hook for 40% of development costs, up from 30%, but also stands to receive milestone payments of up to $100 million based on sales performance which were not included in the original agreement. The shot targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria that causes Lyme disease.
Roots Analysis
FEBRUARY 27, 2024
The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization. What are Affimers : Affimers are small proteins that target and bind molecules on cellular surfaces in a manner analogous to monoclonal antibodies.
The Pharma Data
MARCH 8, 2021
VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine.
Expert insights. Personalized for you.
299 
Let's personalize your content